Advertisement
ALC vs SYK
Which Stock Would AI Choose? Alcon (ALC) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Alcon (ALC) operates in the eye care sector with surgical and vision care products, showing recent price recovery in the $70 range after earlier volatility tied to supply chain concerns.
- Stryker (SYK) focuses on orthopedic and surgical technologies, reporting strong Q2 2026 revenue growth of 9.4% year-over-year and an adjusted EPS beat.
- Both stocks trade in the healthcare equipment space and have experienced negative year-to-date performance amid broader market conditions.
- ALC faces near-term catalyst from its upcoming Q2 earnings report, while SYK demonstrated resilience in recent quarterly results despite post-earnings share pressure.
- Relative momentum favors SYK on recent earnings delivery, though both exhibit sector exposure to medical device demand and regulatory factors.
- Market sentiment reflects cautious positioning for medical technology firms navigating economic and supply dynamics.
Introduction
Investors and traders often compare ALC and SYK due to their positions in the medical technology sector, where demand for advanced devices intersects with economic and healthcare spending trends. Alcon specializes in ophthalmology solutions, while Stryker emphasizes musculoskeletal and surgical technologies. This comparison appeals to those monitoring relative performance, sector rotation within healthcare, and how company-specific catalysts influence short- to medium-term positioning in a market environment shaped by earnings cycles and macroeconomic variables.
ALC Overview and Recent Performance
Alcon Inc. develops and manufactures products for eye care, including surgical equipment and vision care solutions such as contact lenses and intraocular lenses. In recent market activity, shares have traded near the $70–72 range, reflecting a partial recovery following earlier pressure from revenue shortfalls in the first quarter. Broader influences include supply chain considerations and anticipation surrounding the upcoming second-quarter earnings release scheduled for August 10, 2026. Sentiment has remained measured as the company navigates product launches and competitive dynamics in the vision care market.
SYK Overview and Recent Performance
Stryker Corporation provides medical technologies focused on orthopedics, medical and surgical equipment, and neurotechnology. Recent quarterly results highlighted revenue of $6.59 billion, representing a 9.4% year-over-year increase, alongside an adjusted earnings per share figure that exceeded analyst expectations. Share prices have hovered around the $339 level in recent sessions, with performance reflecting both the positive earnings delivery and subsequent market digestion of results. Factors shaping recent activity include ongoing demand in procedural volumes and management of operational challenges such as supply chain elements.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI-powered trading bots designed for various market conditions. Tickeron maintains hundreds of AI Trading Bots that trade thousands of different tickers, yet only those demonstrating the strongest alignment with prevailing market dynamics receive placement in this trending section. The available bots encompass a wide array of trading styles, strategies, timeframes, performance metrics, and ticker sets. Users can explore detailed statistics and historical outcomes across these tools to identify options suited to individual preferences and market environments.
Head-to-Head Comparison
Alcon and Stryker both operate within the medical devices industry but target distinct therapeutic areas, leading to differentiated exposure to procedural volumes and innovation cycles. ALC derives growth primarily from ophthalmic surgery and vision products, while SYK benefits from broader orthopedic and surgical instrumentation demand. Recent momentum has shown SYK delivering more pronounced top-line expansion in its latest reported quarter compared with ALC’s mixed first-quarter outcome. Risk factors for both include regulatory scrutiny, reimbursement pressures, and sensitivity to hospital capital spending. Market sentiment toward SYK has incorporated the recent earnings strength, whereas ALC awaits its next update, creating contrasting near-term visibility profiles within the same healthcare equipment universe.
Tickeron AI Verdict
Based on observable factors including recent earnings consistency and revenue trajectory, Tickeron’s AI would currently assign a modestly higher probability of favorable positioning to SYK relative to ALC. This assessment draws from stronger year-over-year growth delivery and established momentum indicators, tempered by the recognition that upcoming results for ALC could alter relative standing. The evaluation remains probabilistic and centers on trend stability and catalyst visibility rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a StrongBuy and SYK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 2 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- ALC’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- ALC’s TA Score: 4 bullish, 4 bearish.
- SYK’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +5.72% price change this week, while SYK (@Medical/Nursing Services) price change was +1.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.11%. For the same industry, the average monthly price growth was +8.49%, and the average quarterly price growth was +6.88%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.60%. For the same industry, the average monthly price growth was +2.00%, and the average quarterly price growth was -4.72%.
Reported Earning Dates
ALC is expected to report earnings on Nov 10, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.11% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+1.60% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ALC | SYK | ALC / SYK | |
| Capitalization | 36.1B | 130B | 28% |
| EBITDA | 2.54B | 6.44B | 39% |
| Gain YTD | -6.712 | -2.431 | 276% |
| P/E Ratio | 56.68 | 35.15 | 161% |
| Revenue | 10.6B | 25.3B | 42% |
| Total Cash | 1.66B | N/A | - |
| Total Debt | 5.25B | 14.7B | 36% |
ALC | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 92 | 56 | |
SMR RATING 1..100 | 88 | 56 | |
PRICE GROWTH RATING 1..100 | 51 | 51 | |
P/E GROWTH RATING 1..100 | 15 | 82 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (9) in the Medical Specialties industry is in the same range as ALC (32) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew similarly to ALC’s over the last 12 months.
SYK's Profit vs Risk Rating (56) in the Medical Specialties industry is somewhat better than the same rating for ALC (92) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew somewhat faster than ALC’s over the last 12 months.
SYK's SMR Rating (56) in the Medical Specialties industry is in the same range as ALC (88) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew similarly to ALC’s over the last 12 months.
SYK's Price Growth Rating (51) in the Medical Specialties industry is in the same range as ALC (51) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew similarly to ALC’s over the last 12 months.
ALC's P/E Growth Rating (15) in the Hospital Or Nursing Management industry is significantly better than the same rating for SYK (82) in the Medical Specialties industry. This means that ALC’s stock grew significantly faster than SYK’s over the last 12 months.
| ALC | SYK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 58% | N/A |
| Stochastic ODDS (%) | 2 days ago 53% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 49% |
| Advances ODDS (%) | 4 days ago 57% | 4 days ago 56% |
| Declines ODDS (%) | 2 days ago 55% | 2 days ago 52% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 47% |
| Aroon ODDS (%) | 2 days ago 41% | 2 days ago 52% |
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.